Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs

Authors

Mahmoud Al Rifai, Baylor College of Medicine, United States
Dhruv Mahtta, Baylor College of Medicine, United States
David J. Ramsey, Michael E. DeBakey VA Medical Center, United States
Michelle T. Lee, Baylor College of Medicine, United States
Chayakrit Krittanawong, Baylor College of Medicine, United States
Sankar D. Navaneethan, Baylor College of Medicine, United States
L. Parker Gregg, Baylor College of Medicine, United States
Laura A. Petersen, Baylor College of Medicine, United States
Salim S. Virani, Baylor College of Medicine, United StatesFollow

Document Type

Letter to the Editor

Department

Office of the Provost; Cardiology

Abstract

This study using data from the Veterans Affairs (VA) administrative and clinical dataset examined determinants of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use among patients with concomitant atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus. The aim of the present analysis was to identify barriers and facilitators associated with SGLT-2i in a real-world contemporary patient population in order to improve utilization of these guideline-directed agents.

Comments

Issue No are not provided by the author/publisher. This work was published before the author joined Aga Khan University

Publication (Name of Journal)

American heart journal

Recommended Citation

Rifai, M. A., Mahtta, D., Ramsey, D. J., Lee, M. T., Krittanawong, C., Navaneethan, S. D., Gregg, L., Petersen, L. A., Virani, S. S. (2022). Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs. American heart journal, 248, 160-162.
Available at: https://ecommons.aku.edu/provost_office/152